These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24412823)
21. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Lopci E; Santi I; Derenzini E; Fonti C; Savelli G; Bertagna F; Bellò M; Botto B; Huglo D; Morschhauser F; Zinzani P; Fanti S Ann Oncol; 2010 Sep; 21(9):1877-1883. PubMed ID: 20147744 [TBL] [Abstract][Full Text] [Related]
22. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874 [TBL] [Abstract][Full Text] [Related]
23. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Tychyj-Pinel C; Ricard F; Fulham M; Fournier M; Meignan M; Lamy T; Vera P; Salles G; Trotman J Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):408-15. PubMed ID: 24435770 [TBL] [Abstract][Full Text] [Related]
24. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480 [TBL] [Abstract][Full Text] [Related]
25. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542 [TBL] [Abstract][Full Text] [Related]
26. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Le Dortz L; De Guibert S; Bayat S; Devillers A; Houot R; Rolland Y; Cuggia M; Le Jeune F; Bahri H; Barge ML; Lamy T; Garin E Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2307-14. PubMed ID: 20717826 [TBL] [Abstract][Full Text] [Related]
29. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972 [TBL] [Abstract][Full Text] [Related]
31. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296 [TBL] [Abstract][Full Text] [Related]
32. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Tatsumi M; Isohashi K; Matsunaga K; Watabe T; Kato H; Kanakura Y; Hatazawa J Int J Clin Oncol; 2019 Oct; 24(10):1292-1300. PubMed ID: 31165310 [TBL] [Abstract][Full Text] [Related]
33. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680 [TBL] [Abstract][Full Text] [Related]
34. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Kostakoglu L; Goy A; Martinelli G; Caballero D; Crump M; Gaidano G; Baetz T; Buckstein R; Fine G; Fingerle-Rowson G; Berge C; Sahin D; Press O; Sehn L Leuk Lymphoma; 2017 Feb; 58(2):372-381. PubMed ID: 27339738 [TBL] [Abstract][Full Text] [Related]
35. Cerebellum/liver index in pretherapeutic 18F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance. Godard F; Durot E; Durot C; Hoeffel C; Delmer A; Morland D Medicine (Baltimore); 2022 Feb; 101(5):e28791. PubMed ID: 35119047 [TBL] [Abstract][Full Text] [Related]
36. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583 [TBL] [Abstract][Full Text] [Related]
37. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283 [TBL] [Abstract][Full Text] [Related]
38. Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study. Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A Neuro Oncol; 2024 Jul; 26(7):1292-1301. PubMed ID: 38366824 [TBL] [Abstract][Full Text] [Related]
39. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760 [TBL] [Abstract][Full Text] [Related]